| 1.51 -0.06 (-3.82%) | 09-08 10:54 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.92 | 1-year : | 2.25 |
| Resists | First : | 1.64 | Second : | 1.92 |
| Pivot price | 1.53 |
|||
| Supports | First : | 1.43  |
Second : | 1.3 |
| MAs | MA(5) : | 1.53 |
MA(20) : | 1.53 |
| MA(100) : | 1.41 |
MA(250) : | 1.4 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 51.1 |
D(3) : | 54.4 |
| RSI | RSI(14): 50.7 |
|||
| 52-week | High : | 2 | Low : | 1.03 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ GERN ] has closed above bottom band by 37.0%. Bollinger Bands are 59.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 9 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.59 - 1.6 | 1.6 - 1.61 |
| Low: | 1.44 - 1.45 | 1.45 - 1.46 |
| Close: | 1.55 - 1.57 | 1.57 - 1.59 |
Geron Corporation is an advanced-stage biopharmaceutical company dedicated to the creation and market introduction of treatments for myeloid blood cancers. Its primary drug candidate, imetelstat, is a telomerase inhibitor currently undergoing Phase 3 clinical evaluation. This therapy aims to suppress the unchecked proliferation of cancerous stem and progenitor cells characteristic of myeloid hematologic malignancies. Imetelstat is being developed to address low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Established in 1990, Geron's corporate headquarters are located in Foster City, California.
Mon, 07 Sep 2026
Why Did GERN Stock Tumble 10% Pre-Market Today? - Stocktwits
Sat, 05 Sep 2026
Geron Stock Price Forecast. Should You Buy GERN? - StockInvest.us
Wed, 02 Sep 2026
GERN Stock Rises As RYTELO Revenue Beats Expectations - stockstotrade.com
Tue, 18 Aug 2026
Geron Corp.: Management's Plan Taking Shape As Competition Heats Up In Myelofibrosis - Seeking Alpha
Mon, 10 Aug 2026
Geron (GERN) Stock Looks Reasonable On Sales But Weak On Returns - finance.yahoo.com
Sun, 09 Aug 2026
Geron (GERN) Is Up 14.7% After Issuing First RYTELO Revenue Guide And Narrowing Losses - Has The Bull Case Changed? - finance.yahoo.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 642 (M) |
| Shares Float | 556 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 76.5 (%) |
| Shares Short | 80,600 (K) |
| Shares Short P.Month | 69,920 (K) |
| EPS | -0.11 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.34 |
| Profit Margin | -33.1 % |
| Operating Margin | -22.1 % |
| Return on Assets (ttm) | -4.2 % |
| Return on Equity (ttm) | -28.3 % |
| Qtrly Rev. Growth | 17.2 % |
| Gross Profit (p.s.) | 0.18 |
| Sales Per Share | 0.31 |
| EBITDA (p.s.) | -0.06 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -114 (M) |
| Levered Free Cash Flow | -78 (M) |
| PE Ratio | -13.79 |
| PEG Ratio | 0 |
| Price to Book value | 4.45 |
| Price to Sales | 4.76 |
| Price to Cash Flow | -8.52 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|